Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Protara Therapeutics, Inc. (PRTO)
|
Add to portfolio |
|
|
|
| Price: |
$16.60
| | Metrics |
| OS: |
11.3
|
M
| |
13
|
% ROE
|
| Market cap: |
$188
|
M
| |
-69
|
% ROIC
|
|
Net cash:
|
$80.4
|
M
| |
$7.09
|
per share
|
|
EV:
|
$108
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
($39.8)
|
M
| |
|
|
| EPS |
$0.98
| |
17.0
|
x P/E
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 0.0 | 50.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 12.4 |
| Revenue growth | -99.9% | | | | | | -100.0% | 320.0% |
| Cost of goods sold | -70.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 20.9 |
| Gross profit | 70.5 | 50.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -8.5 |
| Gross margin | 207417.6% | 100.0% | | | | | | -68.6% |
| Research and development | 16.8 | 21.1 | 12.0 | 3.9 | 11.8 | 21.7 | 18.9 | |
| General and administrative | 21.0 | 26.6 | 22.5 | 4.0 | 9.5 | 8.7 | 9.8 | 8.5 |
| EBIT | -37.5 | -47.5 | -34.4 | -7.8 | -21.4 | -30.4 | -28.7 | -20.9 |
| EBIT margin | -110426.5% | -94.6% | | | | | | -168.6% |
| Pre-tax income | -66.0 | -47.3 | -34.0 | -7.8 | -20.7 | -30.0 | -28.5 | -21.4 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -66.0 | -47.3 | -34.0 | -7.8 | -20.7 | -36.7 | -28.5 | -21.4 |
| Net margin | -193976.5% | -94.1% | | | | | | -172.7% |
| |
| Diluted EPS | ($5.86) | ($4.21) | ($4.70) | ($3.04) | ($45.80) | ($2.13) | ($1.72) | ($1.31) |
| Shares outstanding (diluted) | 11.3 | 11.2 | 7.2 | 2.6 | 0.5 | 17.3 | 16.6 | 16.3 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|